Literature DB >> 16923539

The complement system in central nervous system diseases.

Horea Rus1, Cornelia Cudrici, Stefan David, Florin Niculescu.   

Abstract

The activation of complement system is important factor in inflammatory, neurodegenerative and cerebrovascular diseases. CNS cells are able to synthesize complement components, and myelin and oligodendrocytes (OLG) are known to activate the classical pathway of complement in vitro in the absence of antibodies. Although activation of the complement system is known to promote tissue injury, recent evidence has also indicated that this process can have neuroprotective effects. In particular, terminal C5b-9 complexes enhance OLG survival both in vitro and in vivo. Complement activation may also reduce the accumulation of amyloid and degenerating neurons by promoting their clearance and suggest that certain inflammatory defense mechanisms in the brain may be beneficial in neurodegenerative disease. Complement system activation plays also an important role in brain damage after ischemic injury or head trauma. These findings strongly suggest that complement activation and membrane assembly of C5b-9 can play a role in injury but can also provide neuroprotection depending on the pathophysiological context.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16923539     DOI: 10.1080/08916930600739605

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  26 in total

Review 1.  Complement in neuroprotection and neurodegeneration.

Authors:  Vijay Yanamadala; Robert M Friedlander
Journal:  Trends Mol Med       Date:  2010-01-28       Impact factor: 11.951

2.  Neuroinflammatory response of the choroid plexus epithelium in fatal diabetic ketoacidosis.

Authors:  William H Hoffman; Manuel F Casanova; Cornelia D Cudrici; Ekaterina Zakranskaia; Roopa Venugopalan; Sukriti Nag; Michael J Oglesbee; Horea Rus
Journal:  Exp Mol Pathol       Date:  2007-01-30       Impact factor: 3.362

Review 3.  The complement system in schizophrenia.

Authors:  Karine R Mayilyan; Daniel R Weinberger; Robert B Sim
Journal:  Drug News Perspect       Date:  2008-05

Review 4.  Myelin as an inflammatory mediator: Myelin interactions with complement, macrophages, and microglia in spinal cord injury.

Authors:  Timothy J Kopper; John C Gensel
Journal:  J Neurosci Res       Date:  2017-07-11       Impact factor: 4.164

5.  Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications.

Authors:  Romain Marignier; Pascale Giraudon; Sandra Vukusic; Christian Confavreux; Jérôme Honnorat
Journal:  Ther Adv Neurol Disord       Date:  2010-09       Impact factor: 6.570

6.  C5b-9-activated, K(v)1.3 channels mediate oligodendrocyte cell cycle activation and dedifferentiation.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Monika Rozycka; Katerina Soloviova; Takahiro Ito; Anil K Singh; Aamer Khan; Philippe Azimzadeh; Maria Andrian-Albescu; Anver Khan; Florin Niculescu; Violeta Rus; Susan I V Judge; Horea Rus
Journal:  Exp Mol Pathol       Date:  2011-04-22       Impact factor: 3.362

Review 7.  Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy.

Authors:  S Scott Whitmore; Elliott H Sohn; Kathleen R Chirco; Arlene V Drack; Edwin M Stone; Budd A Tucker; Robert F Mullins
Journal:  Prog Retin Eye Res       Date:  2014-12-05       Impact factor: 21.198

8.  The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro.

Authors:  R Rampersad; A Barton; Y Sadovsky; D M Nelson
Journal:  Placenta       Date:  2008-09-09       Impact factor: 3.481

Review 9.  The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration.

Authors:  Jessy John Alexander; Aileen Judith Anderson; Scott Robert Barnum; Beth Stevens; Andrea Joan Tenner
Journal:  J Neurochem       Date:  2008-10-24       Impact factor: 5.372

Review 10.  Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Violeta Rus; Takahiro Ito; Sonia Vlaicu; Anil Singh; Horea Rus
Journal:  J Neuroimmunol       Date:  2009-07-04       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.